Tags

Type your tag names separated by a space and hit enter

Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy.
J Allergy Clin Immunol. 2007 Sep; 120(3):602-9.JA

Abstract

BACKGROUND

Despite the use of conventional allergen-specific immunotherapy in clinical practice, more defined, efficient, and safer allergy vaccines are required.

OBJECTIVE

The aim of the study was to obtain hypoallergenic molecules by deleting B-cell epitopes, which could potentially be applied to Parietaria judaica pollen allergy treatment.

METHODS

Three hybrid molecules (Q1, Q2, and Q3) derived from fragments of the 2 major P judaica pollen allergens, Par j 1 and Par j 2, were engineered by means of PCR. Hybrid structures were compared with their natural components by means of circular dichroism, and their biologic activities were compared by using T-cell proliferation assays. Their IgE-binding activity was determined with Western blotting, skin prick tests, and enzyme allergosorbent and ELISA inhibition tests.

RESULTS

The hybrid proteins, especially Q2 and Q3, revealed significantly reduced IgE reactivity compared with the natural allergens, as well as with the whole P judaica extract. Furthermore, in vivo skin prick tests showed that the hybrid proteins had a significantly lower potency to induce cutaneous reactions than the whole P judaica extract. Two (Q1 and Q2) of the 3 hybrid proteins induced a comparable T-cell proliferation response as that produced by the whole extract and natural allergens.

CONCLUSION

Considering its reduced anaphylactogenic potential, together with its conserved T-cell reactivity, the engineered Q2 protein could be used in safe and shortened schedules of allergen-specific immunotherapy against P judaica pollen allergy.

CLINICAL IMPLICATIONS

Recombinant hybrid Q2 is able to induce T-cell proliferation, thus evidencing a potential therapeutic effect. Its reduced IgE-binding capacity envisages an excellent safety profile.

Authors+Show Affiliations

Research and Development Department, Bial-Arístegui, Bilbao, Spain.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17561242

Citation

González-Rioja, Roberto, et al. "Genetically Engineered Hybrid Proteins From Parietaria Judaica Pollen for Allergen-specific Immunotherapy." The Journal of Allergy and Clinical Immunology, vol. 120, no. 3, 2007, pp. 602-9.
González-Rioja R, Ibarrola I, Arilla MC, et al. Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy. J Allergy Clin Immunol. 2007;120(3):602-9.
González-Rioja, R., Ibarrola, I., Arilla, M. C., Ferrer, A., Mir, A., Andreu, C., Martínez, A., & Asturias, J. A. (2007). Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy. The Journal of Allergy and Clinical Immunology, 120(3), 602-9.
González-Rioja R, et al. Genetically Engineered Hybrid Proteins From Parietaria Judaica Pollen for Allergen-specific Immunotherapy. J Allergy Clin Immunol. 2007;120(3):602-9. PubMed PMID: 17561242.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Genetically engineered hybrid proteins from Parietaria judaica pollen for allergen-specific immunotherapy. AU - González-Rioja,Roberto, AU - Ibarrola,Ignacio, AU - Arilla,M Carmen, AU - Ferrer,Angel, AU - Mir,Amparo, AU - Andreu,Carmen, AU - Martínez,Alberto, AU - Asturias,Juan A, Y1 - 2007/06/11/ PY - 2006/12/05/received PY - 2007/04/11/revised PY - 2007/04/30/accepted PY - 2007/6/15/pubmed PY - 2007/11/8/medline PY - 2007/6/15/entrez SP - 602 EP - 9 JF - The Journal of allergy and clinical immunology JO - J Allergy Clin Immunol VL - 120 IS - 3 N2 - BACKGROUND: Despite the use of conventional allergen-specific immunotherapy in clinical practice, more defined, efficient, and safer allergy vaccines are required. OBJECTIVE: The aim of the study was to obtain hypoallergenic molecules by deleting B-cell epitopes, which could potentially be applied to Parietaria judaica pollen allergy treatment. METHODS: Three hybrid molecules (Q1, Q2, and Q3) derived from fragments of the 2 major P judaica pollen allergens, Par j 1 and Par j 2, were engineered by means of PCR. Hybrid structures were compared with their natural components by means of circular dichroism, and their biologic activities were compared by using T-cell proliferation assays. Their IgE-binding activity was determined with Western blotting, skin prick tests, and enzyme allergosorbent and ELISA inhibition tests. RESULTS: The hybrid proteins, especially Q2 and Q3, revealed significantly reduced IgE reactivity compared with the natural allergens, as well as with the whole P judaica extract. Furthermore, in vivo skin prick tests showed that the hybrid proteins had a significantly lower potency to induce cutaneous reactions than the whole P judaica extract. Two (Q1 and Q2) of the 3 hybrid proteins induced a comparable T-cell proliferation response as that produced by the whole extract and natural allergens. CONCLUSION: Considering its reduced anaphylactogenic potential, together with its conserved T-cell reactivity, the engineered Q2 protein could be used in safe and shortened schedules of allergen-specific immunotherapy against P judaica pollen allergy. CLINICAL IMPLICATIONS: Recombinant hybrid Q2 is able to induce T-cell proliferation, thus evidencing a potential therapeutic effect. Its reduced IgE-binding capacity envisages an excellent safety profile. SN - 0091-6749 UR - https://www.unboundmedicine.com/medline/citation/17561242/Genetically_engineered_hybrid_proteins_from_Parietaria_judaica_pollen_for_allergen_specific_immunotherapy_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0091-6749(07)00872-X DB - PRIME DP - Unbound Medicine ER -